Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Repare Therapeutics Inc. (RPTX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 15.31 M | -107,858,000 | 41.82 M | 253.9 M | 243.69 M |
| 2022 | 4.32 M | -154,093,000 | 84.56 M | 364.08 M | 353.98 M |
| 2021 | 3.23 M | -327,114,000 | 80.29 M | 368.72 M | 351.41 M |
| 2020 | 6.16 M | -322,179,000 | 70.26 M | 357.09 M | 346.55 M |
| 2019 | 3.06 M | -93,733,000 | 148.82 M | 102.7 M | 98.57 M |